The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)-Reference-Cited by-同舟云学术

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)

Published:2012-10-12 Issue:2 Volume:9 Page:189-198
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Boxer Adam L.¹,Gold Michael²,Huey Edward³,Hu William T.⁴,Rosen Howard¹,Kramer Joel¹,Gao Fen‐Biao⁵,Burton Edward A.⁶,Chow Tiffany⁷,Kao Aimee¹,Leavitt Blair R.⁸,Lamb Bruce⁹,Grether Megan¹⁰,Knopman David¹¹,Cairns Nigel J.¹²,Mackenzie Ian R.¹³,Mitic Laura¹⁰,Roberson Erik D.¹⁴,Van Kammen Daniel¹⁵,Cantillon Marc¹⁶,Zahs Kathleen¹⁷,Jackson George¹⁸,Salloway Stephen¹⁹,Morris John¹²,Tong Gary²⁰,Feldman Howard²¹,Fillit Howard²²,Dickinson Susan²³,Khachaturian Zaven S.²⁴,Sutherland Margaret²⁵,Abushakra Susan²⁶,Lewcock Joseph²⁷,Farese Robert²⁸,Kenet Robert O.²⁹,LaFerla Frank³⁰,Perrin Steve³¹,Whitaker Steve³²,Honig Lawrence³,Mesulam Marsel M.³³,Boeve Brad¹¹,Grossman Murray³⁴,Miller Bruce L.¹,Cummings Jeffrey L.³⁵

Affiliation:

1. Memory and Aging CenterDepartment of NeurologyUniversity of CaliforniaSan FranciscoCAUSA

2. Allon TherapeuticsVancouverBritish ColumbiaCanada

3. Taub InstituteDepartment of NeurologyColumbia UniversityNew YorkNYUSA

4. Department of NeurologyEmory UniversityAtlantaGAUSA

5. Department of NeurologyUniversity of MassachusettsWorcesterMAUSA

6. Department of NeurologyUniversity of PittsburghPittsburghPAUSA

7. Rotman Research InstituteUniversity of TorontoTorontoOntarioCanada

8. Division of NeurologyDepartment of Medicine, Centre for Molecular Medicine and TherapeuticsUniversity of British ColumbiaVancouverBritish ColumbiaCanada

9. Department of NeurosciencesLerner Research Institute, Cleveland Clinic FoundationClevelandOHUSA

10. Bluefield Project to Cure Frontotemporal DementiaSan FranciscoCAUSA

11. Department of NeurologyMayo ClinicRochesterMNUSA

12. Department of NeurologyWashington University School of MedicineSt. LouisMOUSA

13. Department of Pathology and Laboratory MedicineUniversity of British ColumbiaVancouverBritish ColumbiaCanada

14. Department of NeurologyUniversity of Alabama School of MedicineBirminghamALUSA

15. CNS Drug Development ConsultantPrincetonNJUSA

16. Critical Path InstituteRockvilleMDUSA

17. Grossman Center for Memory Research and Care University of Minnesota School of MedicineMinneapolisMNUSA

18. Department of NeurologyUniversity of Texas Medical BranchGalvestonTXUSA

19. Department of NeurologyBrown University School of MedicineProvidenceRIUSA

20. Bristol Myers SquibbPrincetonNJUSA

21. Division of Neurology, Department of MedicineUniversity of British ColumbiaVancouverBritish ColumbiaCanada

22. Alzheimer's Drug Discovery FoundationNew YorkNYUSA

23. Association for Frontotemporal DegenerationRadnorPAUSA

24. KRA AssociatesPotomacMDUSA

25. National Institute of Neurological Disorders and Stroke National Institutes of HealthBethesdaMDUSA

26. Elan PharmaceuticalsSouth San FranciscoCAUSA

27. GenentechSouth San FranciscoCAUSA

28. Gladstone Institute of Cardiovascular DiseaseSan FranciscoCAUSA

29. Department of MedicineWeill Cornell Medical CollegeNew YorkNYUSA

30. MIND Institute University of CaliforniaIrvineCAUSA

31. ALS Therapy Development InstituteCambridgeMAUSA

32. Omeros CorporationSeattleWAUSA

33. Cognitive Neurology and Alzheimer's Disease Center Northwestern University Feinberg School of MedicineChicagoILUSA

34. Department of NeurologyUniversity of PennsylvaniaPhiladelphiaPAUSA

35. Lou Ruvo Center for Brain Health, Cleveland ClinicLas VegasNVUSA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2012.03.003

Reference67 articles.

1. Off‐label medication use in frontotemporal dementia;Hu B;Am J Alzheimers Dis Other Demen,2010

2. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia

3. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

4. Mixed brain pathologies account for most dementia cases in community-dwelling older persons

5. Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia;Journal of Translational Medicine;2023-06-15

2. Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration;Journal of the Neurological Sciences;2022-11

3. Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update;Drugs & Aging;2022-05-27

4. New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia;Current Opinion in Neurobiology;2022-02

5. GABAergic cortical network physiology in frontotemporal lobar degeneration;Brain;2021-03-12